Global antifungal drug market is expected to reach USD 14.10 billion by 2021, growing at a CAGR of 3.6% between 2015 and 2021.
Sarasota, FL -- (SBWIRE) -- 03/09/2017 -- Zion Market Research has published a new report titled "Antifungal Drug Market by Drug Type (Echinocandins, Azoles, Ployenes, Allylamines and Others) and by Dosage Form (Powders, Ointments, Drugs and Pastes) for Aspergillosis, Dermatophytosis, Candidiasis and Others - Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021". According to the report, the global antifungal drug market accounted for around USD 11.30 billion in 2015 and is expected to reach approximately USD 14.10 billion by 2021, growing at a CAGR of around 3.6% between 2015 and 2021.
Request Free Sample Report @ https://www.zionmarketresearch.com/sample/antifungal-drug-market
Fungi are quite different from bacteria in physical characteristics like size, cellular structure, and chemical composition. Fungi are considered as a "higher beings" when it is compared with bacteria, viruses, and another small micro-organism. It may contain one nucleus or multiple nuclei surrounded by a specific cell wall. However, fungi life cycle may vary from simple to complex and it may reproduce by both asexual and sexual reproduction. Because of the distinct feature, fungi are considered to be much more complex than bacteria. Fungi are also able to adjust and reproduce in abnormal environments such as mammalian tissue. In particular, yeasts is a class of fungi which readily adapts to the human environment and organisms such as Candida species are normal inhabitants of the skin, gastrointestinal tract, female genital tract and urine.
The antifungal drug market is majorly driven by increasing the prevalence of fungal infection across the globe. Furthermore, increasing awareness is a major key factor which is expected to promote the growth of antifungal drug market. Moreover, torpid lifestyle and the compromised immune system can affect antifungal drug market. However, huge penetration of conventional medication coupled with the traditional approach of treatment is the key restraining factor for the growth of anti-fungal drug market. Nonetheless, ongoing research and development in developing anti fungal drugs are likely to bring growth avenues in the future market.
Based on drug type, the global market of the antifungal drug is segmented into five types: echinocandins, azoles, ployenes, allylamines and others. The echinocandins represent the first new class of antifungal drug which was introduced for more than 15 years. This drug acts by inhibiting the cell wall synthesis of fungi (by inhibiting ?-D-glucan). Their potency includes low toxicity, rapid fungicidal activity against most isolates of Candida spp. and predictable constructive kinetics allowing once a day dosing. The first licensed echinocandin product is caspofungin acetate. In terms of revenue, Azole derivatives were the leading drug type segment in antifungal drug market in 2015.
Inquire more about this report @ https://www.zionmarketresearch.com/inquiry/antifungal-drug-market
Based on therapeutic indication, the global market of the antifungal drug is segmented into four types: aspergillosis, dermatophytosis, candidiasis and others. In terms of therapeutic indication, dermatophytosis which is the most common ring worm infections dominates the therapeutic indication market. Dermatophytosis is a common fungal infection of the skin. Infections result in a red, itchy, scaly, circular rash. Hair loss may occur in the affected area of skin especially seen in the child. They are typical of the Trichophyton, Microsporum, or Epidermophyton type. Ringworm infection usually spread by using public showers, contact sports such as wrestling, excessive sweating, contact with animals, obesity, and poor immune function.
Based on the dosage form, the global market of the antifungal drug is bifurcated into four types: powders, ointments, drugs, and pastes. Powder and ointment dosage form dominate the dosage form market in 2015. The growth is attributed due to easy availability of antifungal OTC products in the medical store. It is estimated that the OTC segment of antifungal drugs market is expected to grow at a CAGR of approximately 4.1% within the forecast period.
In terms of geography, North America market was the leading region for antifungal drug market in 2015 in terms of revenue. This growth is supported by wide awareness regarding fungi related infection. North America accounted for approximately more than USD 4.20 billion markets in 2015 which is approximately more than 35% of world total antifungal drug market. Furthermore, lifestyle-related factors such as torpid sedentary lifestyle become very common in the U.S. and European countries which lead to weaken the immune system and thus accelerate the fungal infections. Asia Pacific is expected to be the fastest regional segment for the antifungal drug market in 2015 within the forecast period due to the rapid spread of fungal infection in this region.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global antifungal drug market include Asperqillus, Alternaria, Abbott Laboratories, Pfizer, Glaxosmithkline, Bayer Healthcare, Novartis, Sanofi-Aventis, Merck & Co., Kramer Laboratories, Enzon Pharmaceuticals, and Gilead.
Browse detail report with in-depth TOC @ https://www.zionmarketresearch.com/report/antifungal-drug-market
This report segments the global antifungal drug market as follows:
Global Antifungal Drug Market: Drug Type Analysis
Global Antifungal Drug Market: Therapeutic Indication Analysis
Global Antifungal Drug Market: Dosage Form Analysis
Global Antifungal Drug Market: Regional Segment Analysis
Middle East And Africa
Request a customized copy of report @ https://www.zionmarketresearch.com/custom/534